ArriVent BioPharma, Inc. Common Stock
AVBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $74 | $150 | $163 | $37 |
| Short-Term Investments | $145 | $0 | $0 | $0 |
| Receivables | $1 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $8 | $10 | $19 | $6 |
| Total Curr. Assets | $227 | $160 | $183 | $43 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $48 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $3 | $0 | $0 |
| Total NC Assets | $48 | $3 | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $275 | $163 | $183 | $43 |
| Liabilities | – | – | – | – |
| Payables | $4 | $5 | $3 | $0 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $13 | $7 | $5 | $2 |
| Total Curr. Liab. | $17 | $12 | $8 | $2 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $17 | $12 | $8 | $2 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $304 | $260 | $90 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$238 | -$158 | -$89 | -$52 |
| AOCI | -$0 | $0 | $0 | -$0 |
| Other Equity | $496 | $5 | $3 | $3 |
| Total Equity | $258 | $151 | $174 | $41 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $275 | $163 | $183 | $43 |
| Net Debt | -$74 | -$150 | -$163 | -$37 |